Success for Pfizer’s Trastuzumab Biosimilar in Phase 3 Clinical Trials

U.S. FDA News

Today, Pfizer reported that their trastuzumab biosimilar to Roche’s Herceptin® has shown equivalence in a Phase 3 clinical trial measuring objective response rate (ORR) when taken in combination with paclitaxel to treat HER-positive metastatic breast cancer patients.

Pfizer also reported success in a separate study, REFLECTIONS B3271004, evaluating this biosimilar in early breast cancer patients. Clinical trials and development of Pfizer’s trastuzumab product are ongoing.

Stay tuned for more updates from Big Molecule Watch.

Download PDF

Comments are closed.